Pancreatic cancer
Pancreatic cancer – targeting ALOX12 stops the progression of disease and enhances SoC FFX ( Folfirinox)
Pancreatic Cancer – Stages I-IV
Pancreatic Cancer: Chemotherapy with FOLFIRINOX (FFX: leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is the standard of care (SoC) for PDAC. Despite this aggressive approach (FFX or gemcitabine plus nab-paclitaxel), the median survival of PDAC patients with metastatic disease is less than one year.
Increased plasma levels of 12(S)-HETE (a metabolite of ALOX12) corelates with the incidence of recurrence and metastasis in PDAC patients. We have shown that stromal 12(S)-HETE initiates a paracrine mitogenic effect, promoting PDAC progression and therapy resistance. Inhibiting ALOX12 with the next generation inhibitor, LX12001, stops the progression of the disease in humanized mice models.
Plasma samples from 14 PDAC patients resistant to
chemo show increase activity of ALOX12
ALOX12 stops the progression
of PDAC in mice models.
- ALOX12 modulates PDAC via GPR31 receptor, also expressed in ovarian and esophageal cancer
- Specific inhibition of ALOX12 stops the progression of PDAC in humanized mice
- Completed screening and ADMET studies for LX12001